How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

62,049 results for

Prostatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia Prostatic urethr Prostatic urethral tempor al temporary implant insertion ary implant insertion for lower urinary tr for lower urinary tract symptoms caused b act symptoms caused by y benign prostatic h benign prostatic hyperplasia yperplasia Interventional procedures guidance Published: 30 January 2019 nice.org.uk/guidance/ipg641 Y Y our responsibility our responsibility (...) NICE recommendations wherever possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4only be used in the context of research. 1.2

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

2. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia Prostate artery embolisation for lower urinary Prostate artery embolisation for lower urinary tr tract symptoms caused b act symptoms caused by benign prostatic y benign prostatic h hyperplasia yperplasia Interventional procedures guidance Published: 24 April 2018 nice.org.uk/guidance/ipg611 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after (...) Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of prostate artery embolisation for benign prostatic hyperplasia is adequate to support the use of this procedure © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 Patient selection should be done by a urologist and an interventional radiologist

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

3. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. (Abstract)

Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. A variety of minimally invasive surgical approaches are available as an alternative to transurethral resection of prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). A recent addition to these is prostatic urethral lift (PUL).To assess the effects of PUL for the treatment of LUTS in men with BPH.We performed (...) not find any non-RCTs.Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We planned subgroup analyses by age, prostate volume, and severity of baseline symptoms. We used the GRADE approach to rate the certainty of the evidence.We included two RCTs with 297 participants comparing PUL to sham

2019 Cochrane Controlled trial quality: predicted high

4. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (Abstract)

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

5. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

Prostate cancer screening with prostate-specific antigen (PSA) test Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Prostate cancer... Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline CC BY NC Open access (Published 05 September 2018) Cite this as: BMJ 2018;362:k3581 Population Diagnostic (...) pathway for prostate cancer Localised Stage I or II Stage III or IV Advanced Abnormal biopsy and staging No cancer diagnosis Normal biopsy Still possible to have a biopsy and be diagnosed, based on clinical suspicion No Biopsy Biopsy Normal PSA Elevated PSA or Choices considered in this comparison Prostate-specific antigen (PSA) screening No PSA screening Width of lines proportional to approximate numbers of people Subsequent treatment Surgery Radiation Active surveillance With or without hormonal

2018 BMJ Rapid Recommendations

6. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Full Text available with Trip Pro

Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water-based therapy, combining image guidance and robotics for the removal of prostatic tissue.To assess the effects (...) of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication.We included parallel-group randomised controlled trials (RCTs) and cluster-RCTs, as well

2019 Cochrane

7. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)

Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH) 1 Public Summary Document Application No. 1518 – Endoscopic visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia Applicant: Boston Scientific Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) An application examining the evidence to support an increase in the Medicare Benefits Schedule (MBS) fee for endoscopic visual laser ablation of the prostate (VLAP), also known as photoselective vaporisation of the prostate [PVP] for men with benign prostate hyperplasia (BPH) was received from Boston Scientific Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost

2019 Medical Services Advisory Committee

9. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms 1 Purpose Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society (...) . In the management of bothersome LUTS, it is important that healthcare providers recognize the complex dynamics of the bladder, bladder neck, prostate, and urethra, in addition to the fact that symptoms may result from interactions of these organs as well as with the central nervous system or other systemic diseases (e.g., metabolic syndrome, congestive heart failure). Despite the more prevalent (and often first line) use of medical therapy for men suffering from LUTS attributed to BPH, there still remain

2019 American Urological Association

10. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia (BPH) Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors (...) Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019) Published 2018, Amended 2019 The goal of this revised guideline is to provide a useful reference on the effective evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic

2019 American Urological Association

11. Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Full Text available with Trip Pro

Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological (...) Society of Europe, Société Française de Radiologie, and the British Society of Interventional Radiology - Journal of Vascular and Interventional Radiology Email/Username: Password: Remember me Available now: Use your SIR login to access JVIR. Search Terms Search within Search Share this page Access provided by Volume 30, Issue 5, Pages 627–637.e1 Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms

2019 Society of Interventional Radiology

12. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

13. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report (...) parameter CRF case report form CSR Clinical Study Report CTCAE Common Terminology Criteria for Adverse Events CTGC Central Treatment Guidance Committee DRE digital rectal examination DSMB Data Safety Monitoring Board EC European Commission ECG electrocardiogram EMA European Medicines Agency EPN Extra-prostatic necrosis EQ-5D EuroQol-5D 5-ARI 5-a-reductase inhibitor EU European Union GC Gas Chromatography GCP Good Clinical Practice GLP Good Laboratory Practice GMP Good manufacturing practice HPLC High

2017 European Medicines Agency - EPARs

14. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta- (Abstract)

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta- Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is becoming increasingly more important in guiding local and systemic treatment. Gallium-68 prostate-specific membrane antigen (PSMA) positron emission (...) tomography (PET) has increasingly been utilised globally to assess the local and metastatic burden of prostate cancer, typically in biochemically recurrent or advanced disease. Following our previous meta-analysis, a high-volume series has been reported highlighting the utility of 68Ga-PSMA PET in this setting.To perform a systematic review and meta-analysis to update reported predictors of positive 68Ga-PSMA PET according to prior therapy and proportion of positivity in various anatomical locations

2019 EvidenceUpdates

15. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg T, Wild C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic (...) commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then. Project page URL Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Arteries; Embolization, Therapeutic; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia Language Published

2017 Health Technology Assessment (HTA) Database.

17. Axumin for functional imaging of prostate cancer recurrence

Axumin for functional imaging of prostate cancer recurrence Axumin for functional imaging of prostate cancer Axumin for functional imaging of prostate cancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostate cancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostate cancer. The inno innovativ vative aspects e aspects are that it is a prostate cancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostate cancer recurrence compared with other PET tracers. The intended

2019 National Institute for Health and Clinical Excellence - Advice

18. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (36), 3507-3517 2019 Dec 20 Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration

2020 EvidenceUpdates

19. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia T T r ransurethr ansurethral water jet ablation for lower urinary al water jet ablation for lower urinary tr tract symptoms caused b act symptoms caused by benign prostatic y benign prostatic h hyperplasia yperplasia Interventional procedures guidance Published: 19 September 2018 nice.org.uk/guidance/ipg629 Y Y our responsibility our responsibility This guidance represents the view of NICE (...) possible. 1 1 Recommendations Recommendations 1.1 The evidence on transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia raises no major safety concerns. The evidence on efficacy is limited in quantity. Therefore, this © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 5procedure should only be used with special arrangements for clinical governance, consent, and audit

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

20. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia T T r ransurethr ansurethral water vapour ablation for lower al water vapour ablation for lower urinary tr urinary tract symptoms caused b act symptoms caused by benign y benign prostatic h prostatic hyperplasia yperplasia Interventional procedures guidance Published: 21 August 2018 nice.org.uk/guidance/ipg625 Y Y our responsibility our responsibility This guidance represents the view (...) possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of transurethral water vapour ablation for urinary tract symptoms caused by benign prostatic hyperplasia is © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 This procedure should

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>